Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2022
Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and EfficacyClaire N Harrison, Jacqueline S Garcia, Tim C P Somervaille, et al.
Hematological Oncology|April 3, 2022
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignanciesTariq I Mughal, Naveen Pemmaraju, Rafael Bejar, et al.
Ethnicity & Disease|February 2, 2022
Advancing Inclusive Research: Establishing Collaborative Strategies to Improve Diversity in Clinical TrialsOwen Garrick, Ruben Mesa, Andrea Ferris, et al.
Leukemia|March 9, 2018
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNetTiziano Barbui, Ayalew Tefferi, Alessandro M Vannucchi, et al.
Blood|January 14, 2010
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasmsNils H Thoennissen, Utz O Krug, Dhong Hyun Tony Lee, et al.
Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.
Blood|January 28, 2015
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adultsMichael R Savona, Luca Malcovati, Rami Komrokji, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|June 27, 2025
Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM StudyMassimo Triggiani, Jessica Hobart, Iván Alvarez-Twose, et al.
The Lancet. Haematology|December 7, 2023
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working GroupNicolaus Kröger, Andrea Bacigalupo, Tiziano Barbui, et al.
Future Oncology (London, England)|August 11, 2022
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosisClaire N Harrison, Vikas K Gupta, Aaron T Gerds, et al.
Pageof 18